| 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21,8 Md € | -3.5% | 22,6 Md € | +1.7% | 22,2 Md € | +4.0% | 21,4 Md € | +24.2% | 17,2 Md € | +17.7% | 14,6 Md € | +22.4% | 11,9 Md € | +16.3% | 10,3 Md € | +77.3% | 5,8 Md € | +41.9% | 4,1 Md € | +8.9% | 3,7 Md € | +13.1% | 3,3 Md € | +13.5% | 2,9 Md € | +25.0% | 2,3 Md € | +16.2% | 2,0 Md € | +10.8% | 1,8 Md € | +1.2% | 1,8 Md € | |
| EBITDA | 4,1 Md € | -12.7% | 4,7 Md € | +6.5% | 4,4 Md € | -10.0% | 4,9 Md € | +20.9% | 4,1 Md € | +12.1% | 3,6 Md € | +15.5% | 3,1 Md € | +15.0% | 2,7 Md € | -35.4% | 4,2 Md € | +101.0% | 2,1 Md € | -2.4% | 2,2 Md € | -0.4% | 2,2 Md € | +21.3% | 1,8 Md € | +15.0% | 1,6 Md € | +21.4% | 1,3 Md € | +1.8% | 1,3 Md € | +10.0% | 1,1 Md € | |
| Operating profit | 1,5 Md € | -44.2% | 2,7 Md € | +25.5% | 2,1 Md € | +7.1% | 2,0 Md € | -3.8% | 2,1 Md € | +20.8% | 1,7 Md € | +43.2% | 1,2 Md € | +56.2% | 762,7 M € | -66.3% | 2,3 Md € | +183.0% | 799,4 M € | +58.0% | 505,8 M € | -25.8% | 681,5 M € | +56.5% | 435,6 M € | +87.0% | 232,9 M € | +1924.7% | 11,5 M € | -80.1% | 57,8 M € | -1.4% | 58,6 M € | |
| Profit/loss | 1,5 Md € | -44.5% | 2,6 Md € | +9.0% | 2,4 Md € | +23.5% | 2,0 Md € | -11.3% | 2,2 Md € | +33.6% | 1,7 Md € | +43.5% | 1,2 Md € | +62.0% | 710,5 M € | -66.8% | 2,1 Md € | +174.3% | 781,0 M € | +51.2% | 516,4 M € | -39.8% | 857,9 M € | +19.4% | 718,4 M € | +92.2% | 373,9 M € | +1597.9% | 22,0 M € | +622.4% | -4,2 M € | -110.7% | 39,5 M € | |
| Equity | 11,7 Md € | +11.6% | 10,5 Md € | +6.4% | 9,8 Md € | +12.0% | 8,8 Md € | -28.3% | 12,2 Md € | +22.0% | 10,0 Md € | +19.7% | 8,4 Md € | +15.9% | 7,2 Md € | +10.9% | 6,5 Md € | -18.2% | 8,0 Md € | +10.9% | 7,2 Md € | +7.6% | 6,7 Md € | +14.4% | 5,8 Md € | +10.8% | 5,3 Md € | +7.6% | 4,9 Md € | +0.5% | 4,9 Md € | -0.1% | 4,9 Md € | |
| Total assets | 21,6 Md € | +3.0% | 20,9 Md € | +6.8% | 19,6 Md € | +1.7% | 19,3 Md € | +12.2% | 17,2 Md € | +9.5% | 15,7 Md € | +12.5% | 13,9 Md € | -0.7% | 14,0 Md € | +1.5% | 13,8 Md € | +11.6% | 12,4 Md € | +43.0% | 8,7 Md € | +7.7% | 8,1 Md € | +13.5% | 7,1 Md € | +6.9% | 6,6 Md € | +2.1% | 6,5 Md € | +1.0% | 6,4 Md € | -1.6% | 6,5 Md € | |
| Cash | 24,7 M € | -44.2% | 44,3 M € | +364.8% | 9,5 M € | -69.7% | 31,5 M € | +5.9% | 29,8 M € | +94.0% | 15,3 M € | +25.3% | 12,2 M € | +83.5% | 6,7 M € | -65.0% | 19,1 M € | +119.2% | 8,7 M € | -7.9% | 9,5 M € | -57.6% | 22,3 M € | +259.1% | 6,2 M € | -70.7% | 21,2 M € | +0.3% | 21,2 M € | -7.9% | 23,0 M € | +65.6% | 13,9 M € | |
| Debts | 9,2 Md € | -6.8% | 9,9 Md € | +10.8% | 9,0 Md € | -7.1% | 9,6 Md € | +119.5% | 4,4 Md € | -16.5% | 5,3 Md € | +1.7% | 5,2 Md € | -19.0% | 6,4 Md € | -6.9% | 6,9 Md € | +66.9% | 4,1 Md € | +268.4% | 1,1 Md € | +6.1% | 1,1 Md € | +5.1% | 1,0 Md € | -13.2% | 1,2 Md € | -21.8% | 1,5 Md € | +6.5% | 1,4 Md € | -8.9% | 1,5 Md € | |
| Staff | 5 324,5 | 5 209,9 | 5 159,2 | 5 050,2 | 4 710,6 | 4 617,3 | 4 592,4 | 4 619,1 | 4 569,1 | 4 003 | 3 822 | 3 793,4 | 3 765 | 3 664,6 | 3 712,6 | 3 912,7 | 4 082,3 | |||||||||||||||||
Public limited company · Beerse · incorporated on 23/10/1934 · 5 324,5 ETP
Public limited company profitable and well capitalised. Cash position declining (-44.2%).
Solid counterparty for a standard engagement.
Janssen Pharmaceutica is a Public limited company incorporated in 1934. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Beerse. It employs on average 5 324,5 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette